首页> 外文期刊>BMC Cancer >Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence
【24h】

Comprehensive analyses of competing endogenous RNA networks reveal potential biomarkers for predicting hepatocellular carcinoma recurrence

机译:竞争内源性RNA网络的综合分析揭示了用于预测肝细胞癌复发的潜在生物标志物

获取原文
           

摘要

Hepatocellular carcinoma (HCC) is one of the most common and deadly malignant tumors, with a high rate of recurrence worldwide. This study aimed to investigate the mechanism underlying the progression of HCC and to identify recurrence-related biomarkers. We first analyzed 132 HCC patients with paired tumor and adjacent normal tissue samples from the Gene Expression Omnibus (GEO) database to identify differentially expressed genes (DEGs). The expression profiles and clinical information of 372 HCC patients from The Cancer Genome Atlas (TCGA) database were next analyzed to further validate the DEGs, construct competing endogenous RNA (ceRNA) networks and discover the prognostic genes associated with recurrence. Finally, several recurrence-related genes were evaluated in two external cohorts, consisting of fifty-two and forty-nine HCC patients, respectively. With the comprehensive strategies of data mining, two potential interactive ceRNA networks were constructed based on the competitive relationships of the ceRNA hypothesis. The ‘upregulated’ ceRNA network consists of 6 upregulated lncRNAs, 3 downregulated miRNAs and 5 upregulated mRNAs, and the ‘downregulated’ network includes 4 downregulated lncRNAs, 12 upregulated miRNAs and 67 downregulated mRNAs. Survival analysis of the genes in the ceRNA networks demonstrated that 20 mRNAs were significantly associated with recurrence-free survival (RFS). Based on the prognostic mRNAs, a four-gene signature (ADH4, DNASE1L3, HGFAC and MELK) was established with the least absolute shrinkage and selection operator (LASSO) algorithm to predict the RFS of HCC patients, the performance of which was evaluated by receiver operating characteristic curves. The signature was also validated in two external cohort and displayed effective discrimination and prediction for the RFS of HCC patients. In conclusion, the present study elucidated the underlying mechanisms of tumorigenesis and progression, provided two visualized ceRNA networks and successfully identified several potential biomarkers for HCC recurrence prediction and targeted therapies.
机译:肝细胞癌(HCC)是最常见和最致命的恶性肿瘤之一,全球复发率高。本研究旨在调查HCC进展的机制,并识别与复发相关的生物标志物。我们首先分析了132名HCC患者,具有来自基因表达综合组织(Geo)数据库的配对肿瘤和相邻的正常组织样本,以鉴定差异表达基因(DEGS)。接下来分析来自癌症基因组AtLAS(TCGA)数据库(TCGA)数据库的372 HCC患者的表达谱和临床信息,以进一步验证竞争的内源性RNA(CERNA)网络,并发现与复发相关的预后基因。最后,在两个外部队列中评估了几种与复发相关基因分别由五十二和四十九个HCC患者组成。随着数据挖掘的全面策略,基于Cerna假设的竞争关系构建了两个潜在的互动性Cerna网络。 “上调”的Cerna网络由6个上调的LNCRNA,3个下调的miRNA和5个上调的MRNA组成,并且“下调的网络”包括4个下调的LNCRNA,12个上调的miRNA和67个下调MRNA。 Cerna网络中基因的存活分析表明,20mRNA与无复发存活(RFS)显着相关。基于预后MRNA,用最低绝对收缩和选择操作员(套索)算法建立了一种四基因签名(ADH4,DNASE1L3,HGFAC和MELK)来预测HCC患者的RFS,其性能由接收器评估操作特征曲线。签名也验证了两个外部队列,并显示了HCC患者RFS的有效鉴别和预测。总之,本研究阐明了肿瘤发生和进展的潜在机制,提供了两个可视化的Cerna网络,并成功地确定了几种潜在的HCC复发预测和靶向疗法的潜在生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号